By Adriano Marchese
Telix Pharmaceuticals' said its new drug application in the U.S. for an imaging agent received regulatory approval.
The Melbrourne, Australia-based biopharmaceutical company said Friday that the Food and Drug Administration approved the new drug application for Gozellix.
Gozellix helps with advanced imaging for prostate cancer, making it easier to detect. It provides a longer shelf life and an extended distribution radius compared to existing gallium-based imaging products, Telix said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 21, 2025 06:58 ET (10:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。